Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Frequently asked questions
What sector does Spyre Therapeutics Inc. (SYRE) operate in?
Spyre Therapeutics Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Spyre Therapeutics Inc. (SYRE) current stock price?
As of the latest data, Spyre Therapeutics Inc. stock price is $101.85, with a previous close of $104.09. Spyre Therapeutics Inc. lost -$2.24 in the last trading session, representing a -2.15% loss.
What is Spyre Therapeutics Inc. (SYRE) current market capitalization?
Spyre Therapeutics Inc. market cap is approximately 8.98 billion.
What is Spyre Therapeutics Inc. (SYRE) Earnings Per Share (EPS)?
The trailing EPS is -$1.90, and the forward EPS is -$3.21.
What is Spyre Therapeutics Inc. (SYRE) EBITDA?
Spyre Therapeutics Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -36.20 million.
Does Spyre Therapeutics Inc. (SYRE) pay dividends?
No. Spyre Therapeutics Inc. does not pay a dividend.
What is Spyre Therapeutics Inc. (SYRE) beta (volatility) score?
Spyre Therapeutics Inc. has a beta of 3.026, indicating very high volatility compared to the market.
